Healthcare stocks were higher premarket Thursday, with the State Street Health Care Select Sector SPDR ETF (XLV) gaining 0.3% and the iShares Biotechnology ETF (IBB) advancing 0.9%.
Novartis (NVS) stock was up more than 2% premarket after the company said a phase I/II study of its experimental therapy, del-brax, met both primary and key secondary endpoints in patients with facioscapulohumeral muscular dystrophy.